Mind Medicine Mindmed Inc (MNMD)
$1.02
0.01 (0.99%)
MNMD Stock Quote Delayed 30 Minutes
MNMD Stock: The Latest Psychedelic Drug News MindMed Fans Should Watch
MindMed's LSD trials are facing a regulatory roadblock but MNMD stock isn't being forced down. Here's why investors should watch.
11 Best Stocks to Buy for 2022
He found Apple at $1.49... Oracle at $0.51... Amazon at $46. Now, investing legend Louis Navellier is revealing his Top 11 Stocks for 2022 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
-
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
3.93M
Day's Range
$1.00 - $1.08
52-Week Range
$1.00 - $5.77
Dividend & Yield
N/A (N/A)
MNMD Stock Predictions, Articles, and Mind Medicine Mindmed Inc News
Push the Boundaries of DMT Therapy with Mind Medicine
Ready to explore an under-developed area of psychedelic medicine? If so, then consider a long position in low-priced MNMD stock.
No Matter How the Pandemic Rolls, Mind Medicine Will Prevail
While MNMD stock is controversial due to its underlying psychedelic therapies, the broader narrative is exceptionally compelling.
What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.
So what did the stock market do today? All eyes were on hard-hit Nikola stock and growing interest in mental health startups.
Mind Medicine Has More Obstacles Than Opportunities
MNMD stock could revolutionize mental healthcare with its novel therapeutics, but there are currently too many risks with its business.
MindMed Stock Is Overvalued and Too Risky to Own
MindMed can be the future of psychedelic medicines, but without cash flow from revenue, MNMD stock is nothing to get excited about.
The MindMed Psychedelic Revolution Will Take Years to Come to Fruition
MNMD stock aspires to be a lot to many but could flop. Prices are low, risk is high and speculators could become savants.
Get a Dose of Innovative Science With Mind Medicine
MNMD stock ran high last year, but the story is still being written as Mind Medicine marks progress with its psychedelics-based treatments.
MindMed Can Play a Big Role in the Growing Mental Wellness Industry
MNMD stock is positioned for long-term growth as its LSD, MDMA, and Psilocybin-based treatments have a huge addressable mental wellness market.
Mind Medicine Stock Might Still Be Worth the Risk Here
While MNMD stock is incredibly speculative due to uncertainties of psychedelic therapeutics, the need may transcend the risks.
The Mind Medicine Stock Story Has an Awful Lot of Holes in It
MNMD stock has immense potential, but the plethora of risks surrounding it limit its attractiveness at this time
Mind Medicine Stock Is Not a Trip To Take Just Yet
Psychedelic drugs may eventually be a big market. However, investors in MNMD stock may be getting in a little too early.
